Skip to main content
Figure 4 | Clinical Proteomics

Figure 4

From: LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients

Figure 4

Evaluation of roles of R-value LecT-Hepa, FIB-4, and APRI in predicting treatment outcome of HCV. (A) Serum levels of LecT-Hepa, FIB-4, and APRI from 4 to 12 weeks (R = 12 – 4 weeks) were calculated in SVR (n = 23) and non-SVR (n = 18) patients who achieved RVR during the 48-week course of IFN therapy and underwent a 2-year period of follow-up (4 of the 45 patients were lost to follow-up). Mean values are indicated by a horizontal line and p values were calculated by the Mann–Whitney U test. (B) ROC curves of LecT-Hepa, FIB-4, and APRI for distinguishing patients with SVR from non-SVR. The cut-off values were based on the Youden’s index from the ROC curve. Se, sensitivity; Sp, specificity.

Back to article page